Seeking Alpha

Three partners in the development of diabetes drug Bydureon - Amylin (AMLN), Alkermes (ALKS) and...

Three partners in the development of diabetes drug Bydureon - Amylin (AMLN), Alkermes (ALKS) and Eli Lilly (LLY) - say the treatment didn’t slow heart rate in further testing requested last year by the FDA. ALKS +1.4%, AMLN +6.9%, LLY -0.7% premarket. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs